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Midazolam is a significant and effective drug for control of a life–threatening 
condition, generalized and partial refractory convulsive status epilepticus. The 
goal of this study was evaluation of midazolam efficacy for management 
of this serious disease and its two side effects, hypotension and respiratory 
failure.
Materials & Methods
Our study was done using a quasi experimental method; 22 children with 
generalized refractory convulsive status epilepticus and 13 with partial refractory 
convulsive status epilepticus were enrolled for the study. All patients received 
0.2mg/kg/dose as a bolus intravenous midazolam followed by 1-6 mcg/kg/min 
continuous intravenous midazolam. Following this, termination of seizures as 
well as hypotension and respiratory failure were evaluated.
Results
Midazolam ceased stop convulsions in 81.81% (18) patients with generalized 
seizures, and in 76.92% (10) patients with partial seizures, showing no significant 
difference between these two types of seizures (p=0.52) 
Hypotension was induced in 18.18% (4) patients with generalized seizures and in 
30.70% (4) patients with partial seizures, again difference not significant (p=0.14). 
There was respiratory failure in 21.73% (5) patients with generalized seizure and 
in 7.69% (1) patients with partial seizure, difference not significant.(p=0.09)
Conclusion
There was no significant difference in efficacy and creation of hypotension and 
respiratory failure after continuous intravenous infusion of midazolam between 
generalized and partial refractory convulsive status epilepticus.




Refractory convulsive status epilepticus is a potentially life-threatening neurologic 
emergency that requires immediate medical intervention to prevent many neurologic 
sequelae (1, 2, 3, 4).
Convulsive status epilepticus is defined as a seizure or series of seizures that lasts 30 
minutes or more without regaining consciousness between the seizures (5, 6)
In its most severe form, refractory convulsive status epilepticus, continuous or 
repetitive seizures do not respond to the first anticonvulsant drug therapy and 
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duration of seizure activity is at least 1 hour(7). It has an 
overall mortality of about 5-7% in children (5).
The first line anticonvulsant drugs for initial therapy are 
diazepam, phenobarbital, phenytoin, (8,9).
Midazolam is claimed to be an effective and safe drug 
for treatment of generalized and partial refractory 
convulsive status epilepticus, which is used in different 
methods especially continuous intravenous infusion. 
This drug adheres to the ABA-A receptor and leads to 
increasing activity of neuronal GABA- producing cells, 
controlling the seizures (10, 11).
However, it seems that the anticonvulsive potency of 
midazolam for termination of partial seizures is lower 
than for generalized ones (12), and time lasts quickly 
while; duration for which status epilepticus lasts has a 
significant effect on the outcome( 6).
Our study was done on pediatric patients for evaluation 
of midazolam efficacy in generalized and partial status 
epilepticus. In addition, midazolam has two common 
and significant side effects, hypotension and respiratory 
insufficiency. In some studies, level of hypotension was 
not significant (9, 13). But mild to severe respiratory 
problems have also been reported (14, 15). These two 
side-effects were also investigated. 
Materials & Methods 
Our study, conducted using quasi experimental methods, 
investigated 40 children, 2 months to 16 years of age, 
with refractory convulsive status epilepticus, admitted 
to the pediatric intensive care unit (PICU) of Amirkola 
pediatric hospital in Babol city between 1/1/2004 and 
1/6/2007. This institute is a 150-bed tertiary care and 
referral pediatric hospital. Exclusion criteria were the 
need for prompt neurosurgical intervention, electrolyte 
disturbances and diseases or conditions causing 
hypotension or respiratory insufficiency; ultimately 
5 patients were excluded. Twenty-two patients had 
generalized convulsive status epilepticus, while 13 
patients had partial convulsive status epilepticus.
Methods of patient selection
All patients with convulsive status epilepticus (15), 
received first line anticonvulsant drugs; thus twofold 
intravenous diazepam was given with 10 minute-interval 
in a dose of 0.2mg/kg at a  rate of 0.2mcg/minute for a 
maximum 10 mg(14); if this was unsuccessful, intravenous 
phenytoin was given immediately. The loading dose of 
phenytoin was 15-20mg/kg, infused at the rate of 1mg/
kg/minute. If the status epilepticus was not controlled by 
the preceding strategy, intravenous Phenobarbital was 
initiated in a bolus dose of 10-15mg/kg over 20 minutes 
(16, 17); if seizure was yet uncontrolled, and 30 minutes 
had elapsed since beginning of attack, the patient was 
selected for intravenous midazolam infusion. Variables 
such as age weight, sex, history of seizure, underlying 
diseases, and the time required for control of seizures 
were recoded; and vital parameters including respiratory 
rate, heart rate and blood pressure were documented. 
Cleaning of airway oxygen administration by mask, 
and nasogastric tube insertion were done. Complete 
blood cells count blood chemistries (sodium, potassium, 
calcium, glucose) were measures and other necessary 
specimens were obtained on admission and again 24 
hours later. If prompt measurement of blood glucose 
level was not possible, 5cc/kg bolus of 10% dextrose 
were infused (18) pulse oxymetry and cardiac monitoring 
were used, and the patients were transferred to PICU as 
soon as possible.
Electroencephalography was not used for the diagnosis, 
but was however, performed after the seizure had been 
controlled to diagnose electrical abnormalities. All 
children underwent computed tomography scanning 
or magnetic resonance imaging of the brain and other 
relevant investigations.
Evaluation of midazolam effects
All 35 children received intravenous midazolam at 
0.15mg/kg as a bolus followed by a constant infusion 
starting by 1 mcg/kg/min up to 6mcg/kg/min, increasing 
by 1mg/kg/min, every 15 minutes until complete control 
of seizures was achieved (1). The optimum rate infusion 
at which seizure control was achieved was maintained 
for a period of 24 hours. Subsequently the midazolam 
infusion rate was gradually decreased (by 1mcg/kg/min 
every 2 hours) until tapering was completed (12). If 
seizures were not controlled with the maximum dose of 
the midazolam, other drugs were used.
 Evaluation of midazolam side effects: 
Systolic blood pressure preferably via radial artery, pulse 
and respiratory rates and oxygen saturation by pulse 
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oxymetry, were recorded before infusion of midazolam 
and every 30 minutes until 2 hours, then every 3 hours, 
until 24 hours after infusion.
If systolic blood pressure decreased below 15mmHg it 
was recorded as hypotension (5).
Regarding respiratory side effects, if FIO2 was at least 
60% and oxygen saturation was under 90% or if Pco2 
was over 50mmHg and PH under 7.3, patients were 
considered to have respiratory failure (19).
Statistical analysis: 
Data were analyzed using SPSS software and were 
compared between two groups using Fisher’s exact and 
Mann-Whitney and t-test.
Results 
Of the 35 patients, 22 patients had generalized and 
13 patients had partial refractory convulsive status 
epilepticus (table 1). Mean age, history of antiepileptic 
drug usage, previous seizure, fever, convulsion, and 
mean duration of convulsion after administration of 
midazolam are shown in table 1.
Midazolam effects 
As shown in table 1, midazolam can stop seizures in both 
groups, with a higher rate of success for the generalized 
group (81.81%), but without any significant difference 
(p=0.52). 
Mean time lapse since beginning of midazolam till 
cessation of seizures in the generalized group was 47.4 
minutes, while for the partial group, it was 52.5 minutes; 
mean cumulative time for the two groups was 49.2 
minutes.
Table 2 displays mean midazolam doses that caused 
cessation of convulsion, while mean midazolam dose was 
3.28mcg/kg/min for the two groups without significant 
difference (p=0.5).
Midazolam side effects 
Figure 1 displays hypotension and respiratory failure 
due to midazolam infusion.
Creation of these two side effects had no significant 
difference; P-value for hypotension (0.14) and for 
respiratory insufficiency (0.09).
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Numbers of patients 22 13
Gender ratio: boys to girls 14:8 8:5
Mean age (years) 4.81 2.84
Prior seizure (%) 15(68.8) 10(78.92)
Prior anticonvulsant drug (%) 14(63.63) 9(69.23)
Fever (%) 10(45.45) 6(46.15)
Seizure control (%) 18(81.81) 10(76.92)
Mean time duration until control (min) 47.4 52.5
Table 2. Mean midazolam doses (mcg/kg/min) that caused cessation of convulsion.
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Figure 1. Frequency (%) of midazolam side effects.
Discussion 
In our study, midazolam infusion controlled several 
cases of generalized and partial convulsive status 
epilepticus with no significant discrepancies between 
effects or side effects between these two seizures. 
Minagawa K. and coworkers found that midazolam is an 
appropriate drug for controlling these critical disorders 
(20); another research however claimed that midazolam 
was unsuccessful in the termination of partial refractory 
status epilepticus (12). In our study, although efficacy of 
midazolam had lower efficacy in partial seizures, there 
was no striking discrepancy between them, while mean 
doses for controlling generalized and partial seizures 
were 3.16 and 3.5 mcg/kg/min respectively.
Several studies have determined different means of 
midazolam doses for controlling seizures, (2 to 5.3 mcg/
kg/min) (4, 20, 21). Thus if midazolam has no serious 
side effects, it can be initiated with continuous doses 
higher than 1mcg/kg/min. This approach can prevent 
neurological sequels with earlier control of seizure. 
We suggest further studies be designed with larger 
populations for evaluation of midazolam effects and side 
effects with starting doses above 1 mcg/kg/min.
Hypotension had a frequency of 15-40% in several 
surveys and improved easily (8,11,21). Our study 
revealed hypotension had frequencies of 18.18% and 
30.70% in generalized and partial seizures respectively, 
and improved with intravascular fluid without need for 
vasopressin drugs.
Respiratory failure was mild and did not require 
mechanical ventilation in two previous studies (14, 
22); however Ghofrani and co-workers and Roshan LK 
and colleagues showed it was so severe that 15% and 
40% of patients needed mechanical ventilation (12, 14). 
According to our study, 21.73% and 7.69% of patients 
developed respiratory failure in generalized and partial 
seizures respectively. No children with partial seizures 
needed mechanical ventilation, while 11.43% of patients 
with generalized seizure did.
Both hypotension and respiratory failure occurred 
immediately after the midazolam bolus injection and 
we found no meaningful correlation between these 
side effects and increasing midazolam doses. Thus our 
study revealed that there was no significant difference 
in efficacy and creation of hypotension and respiratory 
failure after continuous intravenous infusion of 
midazolam between generalized and partial refractory 
convulsive status epilepticus.
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